Assignee
REVOLUTION MEDICINES INC
US·40 granted patents·66 pending applications·195 citations·filing 2016–2025
Top patents by PatentIndex Score
106 records- 0198US12465643B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Granted Nov 11, 2025·1 cites·2 claims
- 0298US11952352B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Granted Apr 9, 2024·6 cites·4 claims
- 0398US11608346B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Mar 21, 2023·9 cites·7 claims
- 0497US11566007B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Jan 31, 2023·10 cites·2 claims
- 0597US10989710B2Identifying new therapeutic agentsREVOLUTION MEDICINES INC·Filed 2018·Granted Apr 27, 2021·14 cites·6 claims
- 0696US12280113B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Granted Apr 22, 2025·2 cites·4 claims
- 0796US11739074B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Aug 29, 2023·9 cites·2 claims
- 0896US10533016B2Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2016·Granted Jan 14, 2020·19 cites·16 claims
- 0995US12202845B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2022·Granted Jan 21, 2025·3 cites·6 claims
- 1095US11987590B2Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2021·Granted May 21, 2024·5 cites·18 claims
- 1195US11685749B2C26-linked rapamycin analogs as mTOR inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Jun 27, 2023·5 cites·8 claims
- 1295US11644460B2Identifying new therapeutic agentsREVOLUTION MEDICINES INC·Filed 2020·Granted May 9, 2023·8 cites·10 claims
- 1395US11364300B2C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Jun 21, 2022·6 cites·11 claims
- 1495US11059830B2Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2019·Granted Jul 13, 2021·12 cites·20 claims
- 1595US10980889B1C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitorsREVOLUTION MEDICINES INC·Filed 2020·Granted Apr 20, 2021·8 cites·6 claims
- 1694US12252497B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2022·Granted Mar 18, 2025·3 cites·10 claims
- 1794US12187746B2C26-linked rapamycin analogs as mTOR inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Granted Jan 7, 2025·5 cites·9 claims
- 1894US11690915B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2021·Granted Jul 4, 2023·9 cites·2 claims
- 1994US11168102B1Bicyclic heteroaryl compounds and uses thereofREVOLUTION MEDICINES INC·Filed 2020·Granted Nov 9, 2021·5 cites·18 claims
- 2094US10948495B2Methods and reagents for analyzing protein-protein interfacesREVOLUTION MEDICINES INC·Filed 2018·Granted Mar 16, 2021·12 cites·4 claims
- 2194US10590090B22,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2018·Granted Mar 17, 2020·28 cites·50 claims
- 2293US12048749B2C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitorsREVOLUTION MEDICINES INC·Filed 2022·Granted Jul 30, 2024·3 cites·10 claims
- 2393US2026070930A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Application pending·0 cites
- 2490US2025388608A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Application pending·0 cites
- 2589US9957290B2Derivatives of amphotericin BREVOLUTION MEDICINES INC·Filed 2016·Granted May 1, 2018·8 cites·18 claims
- 2689US2025076289A1Identifying new therapeutic agentsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 2788US12544448B2C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Granted Feb 10, 2026·0 cites·5 claims
- 2888US11220501B2Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8- azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitorREVOLUTION MEDICINES INC·Filed 2021·Granted Jan 11, 2022·3 cites·33 claims
- 2988US2025145643A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 3087US2025085291A1Methods and reagents for analyzing protein-protein interfacesREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 3186US12384750B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Granted Aug 12, 2025·0 cites·8 claims
- 3286US2025101031A1Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 3385US2024044876A1Identifying new therapeutic agentsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
- 3484US2025121077A1Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 3584US2026042740A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Application pending·0 cites
- 3682US12409225B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Granted Sep 9, 2025·0 cites·23 claims
- 3782US12403196B2Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Granted Sep 2, 2025·0 cites·4 claims
- 3880US2025255964A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Application pending·0 cites
- 3980US2025319187A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2025·Application pending·0 cites
- 4079US2023106174A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2022·Application pending·0 cites
- 4177US11673896B2Pyridine compounds as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2019·Granted Jun 13, 2023·1 cites·16 claims
- 4277US2025206715A1Compounds that participate in cooperative binding and uses thereofREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 4376US2025074923A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 4476US2025361245A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 4575US12565476B22,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Granted Mar 3, 2026·0 cites·15 claims
- 4675US11739093B2Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitorsREVOLUTION MEDICINES INC·Filed 2019·Granted Aug 29, 2023·1 cites·18 claims
- 4775US2021405060A1Methods and reagents for analyzing protein-protein interfacesREVOLUTION MEDICINES INC·Filed 2021·Application pending·0 cites
- 4875US2024426833A1Methods and reagents for analyzing protein-protein interfacesREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 4975US2025051306A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2024·Application pending·0 cites
- 5075US2023374035A1Ras inhibitorsREVOLUTION MEDICINES INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 106 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when REVOLUTION MEDICINES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →